Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17191962 | 0.90 | MRGPRX4 (0.58) | MRGPRX4MEN1KMT2APTGER1NR4A2 | |
| SCHEMBL1936167 | 0.85 | MRGPRX4 (0.57) | MRGPRX4MEN1KMT2APTGER1BRD4 | |
| SCHEMBL229472 | 0.83 | MRGPRX4 (0.69) | MRGPRX4MEN1KMT2APTGER1NR4A2 | |
| SCHEMBL31197222 | 0.83 | PTGER1 (0.71) | MRGPRX4MEN1KMT2APTGER1NR4A2 | |
| SCHEMBL5605127 | 0.83 | PTGER1 (0.71) | MRGPRX4MEN1KMT2APTGER1NR4A2 | |
| SCHEMBL2291970 | 0.83 | MRGPRX4 (0.57) | MRGPRX4MEN1KMT2APTGER1NPC1 | |
| SCHEMBL1766201 | 0.83 | RXRA (0.55) | MRGPRX4MEN1KMT2APTGER1BRD4 | |
| SCHEMBL15969027 | 0.83 | MEN1 (0.63) | MRGPRX4MEN1KMT2APTGER1NR4A2 | |
| SCHEMBL30307916 | 0.81 | MEN1 (0.61) | MRGPRX4MEN1KMT2APTGER1NR4A2 | |
| SCHEMBL4876543 | 0.81 | MEN1 (0.61) | MRGPRX4MEN1KMT2APTGER1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083861-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-03-14 | — | — | US | disclosed |
| EP-4221703-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022072517-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083861-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | MRGPRX4 4156/4885MEN1 3193/4885KMT2A 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.